Gilead Sciences
GILD
$130.21
-0.82%
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening infectious diseases, primarily HIV and hepatitis, and is expanding into oncology through acquisitions. As a dominant player in the HIV market and a growing force in cell therapy and oncology, Gilead differentiates itself through its antiviral franchise and strategic bolt-on acquisitions. The current investor narrative centers on Gilead's aggressive acquisition strategy to bolster its oncology pipeline, including the $7.8 billion Arcellx deal and the $3 billion Tubulis acquisition, while managing the decline in its hepatitis C franchise and navigating mixed clinical trial results, such as the Trodelvy-Keytruda lung cancer trial termination.…
GILD
Gilead Sciences
$130.21
Related headlines
Investment Opinion: Should I buy GILD Today?
Rating: Buy. Gilead offers a compelling risk/reward with a 22% upside to the average analyst target of $157.56, supported by a consensus Buy rating (mean 1.69). The core thesis is that Gilead's dominant HIV cash cow funds a transformative oncology pipeline, with valuation at a discount to peers providing a margin of safety.
Supporting evidence: (1) Forward P/E of 13.43x is a 39% discount to the industry median of 22x. (2) Revenue grew 4.39% YoY in Q1 2026, with net margin expanding to 29.0% from 19.7%. (3) Free cash flow yield of 6.7% is attractive relative to the S&P 500 average. (4) Analyst estimates project EPS of $12.93 for fiscal 2026, implying a PEG ratio of 0.01 based on expected growth. The stock's dividend yield of 2.62% adds a total return component.
Risks & Conditions: The biggest risks are pipeline failure (e.g., Arcellx clinical setbacks) and HIV revenue erosion. This Buy rating would downgrade to Hold if the stock approaches the analyst target of $157.56 without new catalysts, or if oncology pipeline data disappoints. It would upgrade to Strong Buy if Arcellx shows positive Phase 3 data or if HIV growth accelerates. Overall, Gilead appears undervalued relative to its cash flow generation and historical P/E range of 10-26x, with the current 17.94x trailing P/E near the midpoint.
Sign up to view all
GILD 12-Month Price Forecast
Gilead's valuation is attractive, with a forward P/E discount to peers and strong cash flow generation. The base case of steady HIV growth and gradual oncology progress is most likely (50% probability), supporting a target of $140-$157.56. However, the bear case (25% probability) of pipeline failure or generic competition could drive the stock to $108-$120. The bullish stance is driven by the valuation margin of safety and robust free cash flow, but confidence is medium due to execution risk in oncology. An upgrade to high confidence would require positive Arcellx data or sustained revenue acceleration above 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $157.15 and implied upside of +20.7% versus the current price.
Average Target
$157.15
0 analysts
Implied Upside
+20.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$120 - $180
Analyst target range
Gilead is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.69 on a 1-5 scale, where 1 is Strong Buy). The distribution leans bullish, with recent upgrades from HSBC (Hold to Buy) and Maxim Group (Hold to Buy), and no downgrades. The average target price is $157.56, implying approximately 21.8% upside from the current price of $129.31. The consensus is clearly bullish, reflecting confidence in Gilead's pipeline and acquisition strategy. The target price range spans from a low of $120.00 to a high of $180.00, a spread of $60 (50% of the low), indicating significant uncertainty. The high target of $180 assumes successful integration of acquisitions like Arcellx and Tubulis, leading to accelerated oncology growth and multiple expansion. The low target of $120 implies concerns about pipeline failures, generic competition to HIV drugs, or disappointing returns from M&A. Recent analyst actions show a positive tilt: HSBC upgraded from Hold to Buy in July 2026, and Maxim Group upgraded from Hold to Buy in May 2026, while Morgan Stanley, Truist, and RBC have maintained their ratings. The wide spread and recent upgrades suggest that while conviction is growing, the outcome remains highly dependent on clinical and regulatory milestones.
Drowning in data?
Find the real signal!
Bulls vs Bears: GILD Investment Factors
Gilead presents a mixed investment case: its dominant HIV franchise generates robust cash flows and expanding margins, while the forward P/E of 13.43x offers a discount to peers and 22% upside to the average analyst target. However, the oncology pipeline faces execution risk after the Trodelvy-Keytruda trial failure, and heavy reliance on HIV revenue creates concentration risk. The bull case currently has stronger evidence given the valuation support and strong free cash flow, but the bear case hinges on whether acquisitions like Arcellx deliver returns. The single most important tension is whether Gilead's aggressive M&A strategy will successfully transform it into a diversified oncology leader or result in value-destructive write-offs.
Bullish
- Strong HIV Franchise Drives Growth: Gilead's core HIV segment, particularly Other HIV products, generated $5.03 billion in Q1 2026, representing 72% of total revenue. This dominant position provides a stable cash flow base, with Q1 2026 revenue up 4.39% YoY to $6.96 billion.
- Expanding Margins Boost Profitability: Net margin improved to 29.0% in Q1 2026 from 19.7% a year ago, while gross margin rose to 79.2% from 76.9%. Operating margin also expanded to 37.2% from 33.6%, reflecting strong cost control and pricing power.
- Attractive Valuation with 22% Upside: With a forward P/E of 13.43x, Gilead trades at a discount to the industry median of ~22x. The average analyst target of $157.56 implies 21.8% upside from the current price of $129.31, supported by a consensus Buy rating.
- Robust Free Cash Flow Supports M&A: Trailing twelve-month free cash flow is $10.23 billion, yielding approximately 6.7% of market cap. This cash generation funds aggressive acquisitions like the $7.8 billion Arcellx deal and $3 billion Tubulis deal without straining the balance sheet.
Bearish
- Oncology Pipeline Setbacks Raise Doubts: Gilead and Merck terminated the Trodelvy-Keytruda lung cancer trial in June 2026, highlighting the high-risk nature of drug development. This failure casts uncertainty on the $7.8 billion Arcellx acquisition and other oncology bets.
- Revenue Concentration in HIV Segment: HIV products account for over 70% of revenue, making Gilead vulnerable to generic competition or pricing pressure. Any erosion in HIV market share could significantly impact top-line growth, as seen with the declining hepatitis C franchise.
- Declining Legacy Hepatitis C and Veklury: Hepatitis C revenue continues to decline, and Veklury (COVID-19) contributed only $144 million in Q1 2026, down from prior peaks. These legacy products are no longer growth drivers, increasing reliance on the unproven oncology pipeline.
- High Debt-to-Equity Ratio Limits Flexibility: With a debt-to-equity ratio of 1.08, Gilead carries significant leverage. While manageable given strong cash flow, it reduces financial flexibility and increases vulnerability to rising interest rates or acquisition integration issues.
GILD Technical Analysis
Gilead's stock is in a range-bound consolidation pattern, with a 1-year price change of +14.23%, significantly underperforming the S&P 500's 16.47% gain. The current price of $129.31 sits at 54.6% of its 52-week range ($108.46 low to $157.29 high), indicating it is closer to the midpoint than extremes, suggesting neither strong momentum nor deep value territory. The stock has been unable to reclaim its 52-week high, reflecting a lack of bullish conviction despite the positive annual return. Short-term momentum shows a mixed picture: the 1-month change is +3.32%, outperforming the S&P 500's 0.78% gain, while the 3-month change is -0.84% versus the S&P 500's +3.50%. This divergence—positive short-term but negative medium-term—suggests a recent bounce within a broader downtrend, potentially a dead cat bounce or early reversal signal. The relative strength index (RSI) is not provided, but the price action indicates a struggle to sustain upward momentum. Key support is at the 52-week low of $108.46, a break below which would signal a bearish breakdown and potential further downside. Resistance is at the 52-week high of $157.29; a breakout above this level would indicate a resumption of the longer-term uptrend. With a beta of 0.343, Gilead is significantly less volatile than the market, meaning it offers downside protection but also limited upside participation during market rallies, which is consistent with its defensive healthcare profile.
Beta
0.34
0.34x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$108-$157
Price range past year
Annual Return
+16.0%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | +0.2% |
| 3m | -1.1% | +3.7% |
| 6m | -8.3% | +8.0% |
| 1y | +16.0% | +18.2% |
| ytd | +7.1% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Gilead's revenue trajectory shows moderate growth, with Q1 2026 revenue of $6.96 billion, up 4.39% year-over-year from $6.667 billion in Q1 2025. However, the multi-quarter trend reveals deceleration: Q4 2025 revenue was $7.924 billion, Q3 2025 was $7.769 billion, and Q2 2025 was $7.081 billion, indicating a sequential decline from Q4 to Q1. The core HIV segment remains the growth driver, with Other HIV products contributing $5.03 billion, while cell therapy products (Yescarta/Tecartus) added $482 million and Trodelvy contributed $402 million. The hepatitis C franchise and Veklury (COVID-19) are declining, with Veklury at only $144 million. The growth narrative hinges on oncology expansion offsetting legacy declines. Profitability is robust: Gilead reported net income of $2.021 billion in Q1 2026, with a net margin of 29.0%, up from 19.7% in Q1 2025. Gross margin remains high at 79.2%, slightly improving from 76.9% a year ago, reflecting strong pricing power and manufacturing efficiency. Operating margin was 37.2%, up from 33.6% in Q1 2025, driven by revenue growth and cost control. The company is solidly profitable with expanding margins, typical for a mature biotech with a dominant HIV franchise. Gilead's balance sheet is healthy but leveraged: debt-to-equity ratio is 1.08, and the current ratio is 1.68, indicating adequate liquidity. Free cash flow (FCF) for Q1 2026 was $2.427 billion, and trailing twelve-month FCF is $10.229 billion, providing ample cash for acquisitions and dividends. Return on equity (ROE) is 37.5%, reflecting strong profitability relative to equity. The FCF yield (FCF/market cap) is approximately 6.7%, suggesting the stock is reasonably valued on a cash flow basis. The company's ability to generate substantial cash internally supports its aggressive M&A strategy without excessive reliance on external financing.
Quarterly Revenue
$7.0B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
79.2%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Since Gilead has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 17.94x, while the forward P/E is 13.43x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests an anticipated increase in earnings, consistent with analyst estimates of EPS growth. Compared to the industry average (Drug Manufacturers - General), Gilead's trailing P/E of 17.94x is at a discount to the sector median of approximately 22x (based on typical pharma valuations), representing a roughly 18% discount. This discount may be justified by Gilead's slower growth relative to high-growth biotechs, but it also reflects market skepticism about its pipeline and revenue diversification. Historically, Gilead's trailing P/E has ranged from about 10x to 26x over the past five years. The current 17.94x is near the midpoint of this range, suggesting it is neither overvalued nor undervalued relative to its own history. The P/E was as low as 10.7x in Q3 2023 and as high as 26.4x in Q1 2025, indicating the stock has traded at a wide range. The current level implies the market is pricing in moderate expectations, not overly optimistic or pessimistic.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Gilead's debt-to-equity ratio of 1.08 indicates moderate leverage, but interest expense of $240 million in Q1 2026 is well covered by operating income of $2.59 billion. The company's heavy reliance on HIV revenue (72% of total) exposes it to generic competition, especially as key patents expire. While free cash flow of $10.23 billion TTM is strong, the $7.8 billion Arcellx acquisition and $3 billion Tubulis deal increase integration risk and could pressure returns if pipeline milestones are missed. Net margin expansion to 29% is positive but may be unsustainable if R&D spending rises to support the oncology pipeline.
Market & Competitive Risks: Gilead's forward P/E of 13.43x is a discount to the industry median of 22x, but this discount may persist if the market remains skeptical of the oncology pivot. The stock's beta of 0.343 provides downside protection but also limits upside in bull markets, contributing to its 6-month underperformance (-4.87% vs. S&P 500 +7.21%). Competitive threats include new HIV treatments from other pharma companies and pricing pressure from government programs. The termination of the Trodelvy-Keytruda trial in June 2026 highlights competitive risk in the oncology space, where Gilead lags behind established players like Merck and Bristol-Myers Squibb.
Worst-Case Scenario: If the Arcellx acquisition fails to yield a commercial success and HIV revenue declines due to generic competition, Gilead's stock could fall to its 52-week low of $108.46, representing a 16.1% decline from the current price of $129.31. In a severe scenario where multiple acquisitions prove value-destructive and the dividend is cut, the stock could test the analyst low target of $120.00, a 7.2% drop. Historical max drawdown of -22.03% suggests a potential decline to ~$100.80, implying a 22% loss from current levels.
FAQ
The primary risk is pipeline failure, as seen with the Trodelvy-Keytruda trial termination, which could impair the $7.8 billion Arcellx acquisition. Second, HIV revenue concentration (72% of total) exposes Gilead to generic competition or pricing pressure, especially as patents expire. Third, the debt-to-equity ratio of 1.08 limits financial flexibility, though interest coverage is strong. Fourth, the stock's low beta (0.343) means it underperforms in bull markets, as evidenced by its 6-month return of -4.87% vs. the S&P 500's +7.21%. The most severe risk is a combination of pipeline failure and HIV revenue decline, which could drive the stock to the 52-week low of $108.46.
The 12-month forecast is moderately bullish, with a base case (50% probability) targeting $140-$157.56, driven by steady HIV growth and gradual oncology progress. The bull case (25% probability) sees the stock reaching $157.56-$180 if pipeline data is positive, while the bear case (25% probability) could see a decline to $108.46-$120 if pipeline fails or generic competition emerges. The average analyst target of $157.56 implies 21.8% upside from the current price of $129.31. The most likely scenario is the base case, assuming HIV revenue grows 3-4% and no major pipeline setbacks.
Gilead appears undervalued relative to its peers and its own history. The trailing P/E of 17.94x is below the 5-year average of ~20x and well below the industry median of 22x. The forward P/E of 13.43x implies the market expects earnings growth, which is supported by analyst estimates of $12.93 EPS for fiscal 2026. On a price-to-sales basis, the PS ratio of 5.19x is reasonable for a biotech with 79% gross margins. The free cash flow yield of 6.7% further supports undervaluation. However, the discount reflects skepticism about the oncology pipeline, so the stock is fairly valued if pipeline fails but undervalued if it succeeds.
Gilead is a good buy for investors seeking a defensive healthcare stock with a 2.62% dividend yield and 22% upside to the average analyst target of $157.56. The forward P/E of 13.43x is a 39% discount to the industry median, providing a valuation cushion. However, the stock carries pipeline execution risk, as highlighted by the terminated Trodelvy-Keytruda trial. It is best suited for long-term investors who can tolerate moderate downside to the 52-week low of $108.46 (-16%) in exchange for steady cash flow and potential oncology upside. Short-term traders may find the low beta (0.343) and range-bound price action less attractive.
Gilead is better suited for long-term investment due to its low beta (0.343), stable dividend yield (2.62%), and dependence on pipeline catalysts that may take 12-24 months to materialize. The stock's range-bound price action and underperformance vs. the S&P 500 make it less attractive for short-term trading. A minimum holding period of 2-3 years is recommended to allow the oncology pipeline to mature and acquisitions to integrate. Long-term investors benefit from the 6.7% free cash flow yield and potential for multiple expansion as pipeline risks recede.
